Is XOMA Corp (NASDAQ:XOMA) A Real Gem?
Gevokizumab is XOMA Corp (NASDAQ:XOMA)’s lead drug-candidate that was designed to meet various therapeutic and commercial challenges that are an inherent part of IL-I inhibitors. This drug was perfect for infrequent and high-dosage treatment as it can be dosed only one a month in comparison to Ilaris which requires daily dosing. This is because it has a longer-life of around 22 days. In 2011, the company also entered into a collaboration and licensing agreement with Servier Laboratories for developing and commercializing this drug for various indications. As per this agreement, the drug is now being evaluated in a Phase3 trial dubbed EYEGUARD. The objective of this study is to determine whether gevokizumab is useful in the treatment of acute -non-infectious uveitis and in the prevention of disease-flares in patients suffering from this disease. In addition, the company has a POC in progress that will explore the safety and the efficacy of the drug for different indications. XOMA Corp (NASDAQ:XOMA) expects the Phase3 indication to be selected by the 2013 Q4.
In Tuesday’s trading, XOMA Corp (NASDAQ:XOMA) dropped by 5.22%. The opening price of the shares was $4.78, which was also the intraday high and dipped to a close of $4.54. Approximately 1.27 million shares were traded on Tuesday while an average volume of 1.16 million shares were traded over a 30 day period. The 52-week low of XOMA Corp (NASDAQ:XOMA) shares is $2.37 and its 52-week high is $5.54. The company has a market capitalization of $411.40 million.
About the company
XOMA Corp (NASDAQ:XOMA) is involved in discovering and developing various antibody-based therapeutics. Gevokizumab is its lead drug-candidate. This is a humanized monoclonal-allosteric modulating anti-body that is designed to inhibit pro-inflammatory-cytokine interleukin-1 beta. XOMA Corp (NASDAQ:XOMA)’s pre-clinical pipeline includes different classes of anti-bodies that either activate or sensitize XMet, the insulin-receptor in vivo.